A Comparison of Mometasone Furoate DPI Versus Budesonide DPI in Budesonide DPI in Asthmatics (Study P04880)
Status:
Completed
Trial end date:
2009-07-01
Target enrollment:
Participant gender:
Summary
This study will be an open-label, parallel-group comparison of Mometasone Furoate Dry Powder
Inhaler (MF-DPI) 200 mcg once daily in the evening with two puffs vs. Budesonide Dry Powder
Inhaler (BUD-DPI) 200 mcg twice daily with two puffs each time in patients previously treated
with inhaled corticosteroids (ICS) or without ICS with diagnosed mild persistent or moderate
persistent asthma (classified as Global Initiative For Asthma, 2005) in the previous 4 weeks.
The primary efficacy endpoint is percent change from baseline in FEV1.